CLBS

Caladrius Biosciences Stock Price

2.42
0.00 (0.0%)
2.42
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Caladrius Biosciences Inc CLBS NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Previous Close Last Traded
0.00 0.0% 2.42 0.00 0.00 0.00 2.42 04:00:00
Bid Price Ask Price Spread Spread % News
2.38 2.50 0.12 4.8% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 2.42 USD

Caladrius Biosciences Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 37.64M 15.55M 14.03M $ - $ - -1.88 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Caladrius Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CLBS Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week2.342.64992.242.44543,2970.083.42%
1 Month2.283.21012.052.611,197,0300.146.14%
3 Months2.013.21011.652.26812,7330.4120.4%
6 Months2.823.21011.052.22441,233-0.40-14.18%
1 Year2.633.641.052.25232,595-0.21-7.98%
3 Years4.0011.651.053.72131,593-1.58-39.5%
5 Years12.3020.301.055.94136,565-9.88-80.33%

Caladrius Biosciences Description

Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company developing cellular therapies designed to reverse, not manage, disease. The company's product candidates include: CLBS119, for the repair of lung damage found in patients with severe COVID-19 infection who experienced respiratory failure, clinical trial to be initiated in 3Q2020 (USA); CLBS12, recipient of a SAKIGAKE (Japan) and ATMP (Europe) designations, eligible for early conditional approval for the treatment of critical limb ischemia based on an ongoing clinical trial (Japan); CLBS16, subject of the completed proof-of-concept ESCaPE-CMD clinical and planned Phase 2B (U.S.A.); and CLBS14, a Phase 3 ready clinical program in no option refractory disabling angina and recipient of a RMAT designation (USA).


Your Recent History
NASDAQ
CLBS
Caladrius ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.